BC 11 hydrobromideSelective urokinase inhibitor CAS# 443776-49-6 |
- Fulvestrant
Catalog No.:BCC1081
CAS No.:129453-61-8
- (Z)-2-decenoic acid
Catalog No.:BCC1295
CAS No.:15790-91-7
- Bazedoxifene acetate
Catalog No.:BCC1412
CAS No.:198481-33-3
- (E)-2-Decenoic acid
Catalog No.:BCC1292
CAS No.:334-49-6
- Toremifene
Catalog No.:BCC2010
CAS No.:89778-26-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 443776-49-6 | SDF | Download SDF |
PubChem ID | 78243712 | Appearance | Powder |
Formula | C8H12BBrN2O2S | M.Wt | 290.97 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 20 mM in water with gentle warming | ||
Chemical Name | [4-(carbamimidoylsulfanylmethyl)phenyl]boronic acid;hydrobromide | ||
SMILES | B(C1=CC=C(C=C1)CSC(=N)N)(O)O.Br | ||
Standard InChIKey | PAFZAMOVHIRQOD-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C8H11BN2O2S.BrH/c10-8(11)14-5-6-1-3-7(4-2-6)9(12)13;/h1-4,12-13H,5H2,(H3,10,11);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective urokinase (uPA) inhibitor (IC50 = 8.2 μM). Exhibits no activity at 8 other related enzymes. Inhibits clot lysis with no effect on clot formation. Also decreases viability of MDA-MB231 breast cancer cells in vitro. |
BC 11 hydrobromide Dilution Calculator
BC 11 hydrobromide Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.4368 mL | 17.1839 mL | 34.3678 mL | 68.7356 mL | 85.9195 mL |
5 mM | 0.6874 mL | 3.4368 mL | 6.8736 mL | 13.7471 mL | 17.1839 mL |
10 mM | 0.3437 mL | 1.7184 mL | 3.4368 mL | 6.8736 mL | 8.592 mL |
50 mM | 0.0687 mL | 0.3437 mL | 0.6874 mL | 1.3747 mL | 1.7184 mL |
100 mM | 0.0344 mL | 0.1718 mL | 0.3437 mL | 0.6874 mL | 0.8592 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Selective urokinase (uPA) inhibitor (IC50 = 8.2 μM). Exhibits no activity at 8 other related enzymes. Inhibits clot lysis with no effect on clot formation.
- Z-DL-Met-OH
Catalog No.:BCC2759
CAS No.:4434-61-1
- SF 11
Catalog No.:BCC7805
CAS No.:443292-81-7
- Isopedicin
Catalog No.:BCN4633
CAS No.:4431-42-9
- Ligustilide
Catalog No.:BCN1031
CAS No.:4431-01-0
- Metronidazole
Catalog No.:BCC9046
CAS No.:443-48-1
- Tabersonine
Catalog No.:BCN5496
CAS No.:4429-63-4
- Methyl isodrimeninol
Catalog No.:BCN5495
CAS No.:442851-27-6
- Anguizole
Catalog No.:BCC1365
CAS No.:442666-98-0
- JW 67
Catalog No.:BCC6251
CAS No.:442644-28-2
- CK 666
Catalog No.:BCC6088
CAS No.:442633-00-3
- CK-636
Catalog No.:BCC5107
CAS No.:442632-72-6
- Aspertine C
Catalog No.:BCN2153
CAS No.:442155-62-6
- JNJ-7706621
Catalog No.:BCC2171
CAS No.:443797-96-4
- 3-Chloro-4-(3-fluorobenzyloxy)nitrobenzene
Catalog No.:BCC8626
CAS No.:443882-99-3
- Norkhellol
Catalog No.:BCN5497
CAS No.:4439-68-3
- Glycosmisic acid
Catalog No.:BCN3650
CAS No.:443908-19-8
- Vandetanib (ZD6474)
Catalog No.:BCC3883
CAS No.:443913-73-3
- 1,4-Benzodioxane-6-carboxylic acid
Catalog No.:BCC8422
CAS No.:4442-54-0
- 2-Cyclohexylethylamine
Catalog No.:BCN1794
CAS No.:4442-85-7
- Norwogonin
Catalog No.:BCN3190
CAS No.:4443-09-8
- Pazopanib (GW-786034)
Catalog No.:BCC1286
CAS No.:444731-52-6
- CMX001
Catalog No.:BCC4106
CAS No.:444805-28-1
- Cyclopamine
Catalog No.:BCN2964
CAS No.:4449-51-8
- Warangalone
Catalog No.:BCN4788
CAS No.:4449-55-2
Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells.[Pubmed:26029857]
Molecules. 2015 May 28;20(6):9879-89.
BC-11 is an easily synthesized simple thiouronium-substituted phenylboronic acid, which has been shown to be cytotoxic on triple negative MDA-MB231 breast cancer cells by inducing a perturbation of cell cycle when administered at a concentration equal to its ED50 at 72 h (117 muM). Exposure of cells to BC-11, either pre-absorbed with a soluble preparation of the N-terminal fragment of urokinase-plasminogen activator (uPa), or in co-treatment with two different EGFR inhibitors, indicated that: (i) BC-11 acts via binding to the N-terminus of the enzyme where uPa- and EGF receptor-recognizing sites are present, thereby abrogating the growth-sustaining effect resulting from receptor binding; and (ii) the co-presence of the EGFR inhibitor PD153035 potentiates BC-11's cytotoxicity. Exposure of cells to a higher concentration of BC-11 corresponding to its ED75 at 72 h (250 muM) caused additional impairment of mitochondrial activity, the production of reactive oxygen species and promotion of apoptosis. Therefore, BC-11 treatment appears to show potential for the development of this class of compounds in the prevention and/or therapy of "aggressive" breast carcinoma.